PATENT CLAIMS

1. A crystalline ~~Compound~~ compound of formula **(I)**



(I),

~~optionally in the form of the tautomers thereof.~~

~~2. Crystalline compound of formula (I) according to claim 1,~~ characterised in that reflections in the X-ray powder diagram occur at d_{hkl} values of 7.11, 5.77, 4.69, 4.36, 4.15, 3.85 and 3.61 Å, optionally in the form of the tautomers thereof.

2. The crystalline compound of formula (I) according to claim 1, further characterized in that its X-ray powder diffraction pattern comprises peaks at 12.43, 15.33, 18.92, 20.37, 21.38 and 24.67 degrees 2θ when measured using CuKα radiation.

~~3. Compound according to claim 1 or 2 for use as a medicament.~~

~~4. Compound according to claim 1 or 2 for the treatment of inflammatory or allergic diseases of the airways.~~

~~5. Process for the stereoselective preparation of the compound of formula (I) according to claim 1, optionally in the form of the tautomers thereof:~~



~~(I),~~

~~characterised in that the process comprises reaction steps (A) to (M), wherein~~

~~(A) is the reaction of 1,4-cyclohexanedione-mono-ethyleneketal to form a compound of formula (1)~~



(1),

(B) is the reaction of a compound of formula (1) to form the compound of formula (2)



(2),

(C) is the reaction of a compound of formula (2) to form the compound of formula (3)



(3)

(D) is the reaction of a compound of formula (3) with a protective group reagent to form the compound of formula (4)



(4),

(E) is the reduction of a compound of formula (4) to form the compound of formula (5)



(5)

(F) is the reaction of a compound of formula (5) to form a compound of formula (6)



(6)

(G) is the reaction of a compound of formula (6) with a compound of formula (13) to form a compound of formula (7)



(13)



(7)

(H) is the reaction of a compound of formula (7) to form a compound of formula (8a) or its tautomeric form (8b),



(8a)



(8b)

(I) is the chlorination of the compound of formula (8a) or (8b) to form a compound of formula (9)



(9)

(J) + (K) is the reaction of the compound of formula (9) with 3-chloro-2-fluoroaniline and the cleaving of a protective group to form a compound of formula (11) or (11A)



(11)



x HCl (11A)

(L) is the cleaving of another protective group to form the compound of formula (II)



(II)

(M) is the reaction of the compound of formula (II) with maleic acid to form a compound of formula (I), optionally in the form of the tautomers thereof,



~~(I),~~

~~wherein process steps (A) to (M) take place successively in the sequence specified.~~

~~6. Process according to claim 5, wherein process steps (J+K) are replaced by steps (N+O), wherein~~

~~(N+O) is the cleaving of a protective group of the compound of formula (9) to form the compound of formula (12) and subsequent reaction with 3-chloro-2-fluoroaniline to form the compound of formula (11) or (11A) according to claim 6~~



~~(12).~~

~~7. Process according to claim 5 or 6, for the stereoselective preparation of a compound of formula (I), characterised in that the process consists of process steps (I), (J), (K), (L), and (M) or of process steps (I),(N), (O), (L) and (M), wherein the process steps (I) to (M) in each case take place successively in the sequence specified.~~

~~8. Process according to claim 6 or 7 for the stereoselective preparation of a compound of formula (II), characterised in that the process consists of process steps (I), (J), (K) and (L), or of process steps (I),(N), (O) and (L), wherein the process steps (I) to (L) in each case take place successively in the sequence specified.~~

~~9. Process step (G) according to claim 5.~~

~~10. Process step (I) according to claim 5.~~

~~11. Intermediate of formula (6) according to claim 5, optionally in the form of the tautomers thereof.~~

~~12. Intermediate of formula (7) according to claim 5, optionally in the form of the tautomers thereof.~~

~~13. Intermediate of formula (8) according to claim 65, optionally in the form of the tautomers thereof.~~

~~14. Intermediate of formula (9) according to claim 5, optionally in the form of the tautomers thereof.~~

~~15. Intermediate of formula (11) or (11A) according to claim 5, optionally in the form of the tautomers thereof.~~

~~16~~3. ~~Pharmaceutical~~ A pharmaceutical composition containing ~~a~~ the compound of formula **(I)** according to claim 1.

~~17~~4. ~~Medicament combinations~~ A pharmaceutical composition which contains~~, as a further active substance, in addition to one or more~~ the compounds of formula **(I)** according to claim 1~~,~~ and one or more compounds selected from among the categories of the betamimetics, anticholinergics, corticosteroids, PDE4-inhibitors, LTD4-receptor antagonists, LTB4-receptor antagonists, inhibitors of MAP kinases, bradykinin receptor antagonists, endothelin receptor antagonists, CXCR1 and/or CXCR2 receptor antagonists and antitussives, or double or triple combinations thereof.